EDCTP and GHIT Fund co-fund the development of the pediatric Praziquantel formulation for schistosomiasis
Publish Date
08 DEC 2017
Overview
Two important donors working together for the first time
On December 8th, the European & Developing Countries Clinical Trials Partnership (EDCTP) and The Global Health Innovative Technology (GHIT) Fund announced that they will be co-funding the phase III clinical study conducted by the Pediatric Praziquantel Consortium, led by Merck KGaA, Darmstadt, Germany. This study aims to provide clinical data and support for registration of a new praziquantel (PZQ) tablet formulation to treat schistosomiasis in preschool-aged children.
The joint investment is the first action of a new partnership between EDCTP and GHIT, initiated to support product development research. It certainly represents a great achievement for the Consortium and for Merck KGaA, Darmstadt, Germany, and a significant step forward in contribution to the elimination agenda for schistosomiasis.
Click here for more information on the Consortium.